Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John T Hunt

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
ACS Medicinal Chemistry Letters|February 19, 2021
Discovery and Preclinical Evaluation of BMS-986242, a Potent, Selective Inhibitor of Indoleamine-2,3-dioxygenase 1Emily C Cherney, Liping Zhang, Susheel Nara, et al.
Journal of Medicinal Chemistry|March 31, 2006
Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitorRajeev S Bhide, Zhen-Wei Cai, Yong-Zheng Zhang, et al.
Journal for Immunotherapy of Cancer|January 7, 2021
Enhanced antitumor immunity by a novel small molecule HPK1 inhibitorDan You, Stephen Hillerman, Gregory Locke, et al.
Bioorganic & Medicinal Chemistry Letters|April 11, 2015
BMS-871: a novel orally active pan-Notch inhibitor as an anticancer agentWeifang Shan, Aaron Balog, Claude Quesnelle, et al.
Journal of Medicinal Chemistry|March 19, 2004
N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agentRaj N Misra, Hai-yun Xiao, Kyoung S Kim, et al.
Journal of Medicinal Chemistry|August 23, 2002
Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activitiesKyoung Soon Kim, S David Kimball, Raj N Misra, et al.
Journal of Medicinal Chemistry|March 6, 2009
Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamilyGretchen M Schroeder, Yongmi An, Zhen-Wei Cai, et al.
ACS Medicinal Chemistry Letters|May 26, 2015
Discovery of Clinical Candidate BMS-906024: A Potent Pan-Notch Inhibitor for the Treatment of Leukemia and Solid TumorsAshvinikumar V Gavai, Claude Quesnelle, Derek Norris, et al.
ACS Medicinal Chemistry Letters|July 16, 2021
Conformational-Analysis-Guided Discovery of 2,3-Disubstituted Pyridine IDO1 InhibitorsEmily C Cherney, Liping Zhang, Weiwei Guo, et al.
Journal of Medicinal Chemistry|September 20, 2021
Discovery and Preclinical Pharmacology of an Oral Bromodomain and Extra-Terminal (BET) Inhibitor Using Scaffold-Hopping and Structure-Guided Drug DesignAshvinikumar V Gavai, Derek Norris, George Delucca, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
ACS Medicinal Chemistry Letters|February 19, 2021
Discovery and Preclinical Evaluation of BMS-986242, a Potent, Selective Inhibitor of Indoleamine-2,3-dioxygenase 1Emily C Cherney, Liping Zhang, Susheel Nara, et al.
Journal of Medicinal Chemistry|March 31, 2006
Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitorRajeev S Bhide, Zhen-Wei Cai, Yong-Zheng Zhang, et al.
Journal for Immunotherapy of Cancer|January 7, 2021
Enhanced antitumor immunity by a novel small molecule HPK1 inhibitorDan You, Stephen Hillerman, Gregory Locke, et al.
Bioorganic & Medicinal Chemistry Letters|April 11, 2015
BMS-871: a novel orally active pan-Notch inhibitor as an anticancer agentWeifang Shan, Aaron Balog, Claude Quesnelle, et al.
Journal of Medicinal Chemistry|March 19, 2004
N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agentRaj N Misra, Hai-yun Xiao, Kyoung S Kim, et al.
Journal of Medicinal Chemistry|August 23, 2002
Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activitiesKyoung Soon Kim, S David Kimball, Raj N Misra, et al.
Journal of Medicinal Chemistry|March 6, 2009
Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamilyGretchen M Schroeder, Yongmi An, Zhen-Wei Cai, et al.
ACS Medicinal Chemistry Letters|May 26, 2015
Discovery of Clinical Candidate BMS-906024: A Potent Pan-Notch Inhibitor for the Treatment of Leukemia and Solid TumorsAshvinikumar V Gavai, Claude Quesnelle, Derek Norris, et al.
ACS Medicinal Chemistry Letters|July 16, 2021
Conformational-Analysis-Guided Discovery of 2,3-Disubstituted Pyridine IDO1 InhibitorsEmily C Cherney, Liping Zhang, Weiwei Guo, et al.
Journal of Medicinal Chemistry|September 20, 2021
Discovery and Preclinical Pharmacology of an Oral Bromodomain and Extra-Terminal (BET) Inhibitor Using Scaffold-Hopping and Structure-Guided Drug DesignAshvinikumar V Gavai, Derek Norris, George Delucca, et al.
Pageof 4